Novel biomarker for amnesiac mild cognitive impairment

Takeaway

  • In people with amnesiac mild cognitive impairment (aMCI) synaptic density loss is inversely correlated with pathologic tau deposition in the medial temporal lobe (MTL).

Why this matters

    Multitracer positron emission tomography–magnetic resonance imaging (PET-MRI) investigation may serve as a clinical biomarker for the diagnosis, prognosis and progression monitoring of aMCI.